A neurofibromatosis type 1 genetic test looks for a disease-causing variant in NF1, the gene that encodes neurofibromin. NF1 is a common inherited tumor-predisposition and multisystem condition associated with café-au-lait macules, skin-fold freckling, neurofibromas, plexiform neurofibromas, learning or attention difficulties, bone abnormalities, vascular disease, and several tumor risks. Genetic testing can confirm the diagnosis in a young child with incomplete features, distinguish NF1 from Legius syndrome, identify mosaic disease, and enable targeted testing of relatives. A pathogenic or likely pathogenic NF1 variant is meaningful, but it does not predict how many tumors will develop or how severe the condition will be. A negative result does not exclude NF1 when clinical criteria are met, especially if the assay did not include RNA analysis, deletion testing, or evaluation for mosaicism. Regardless of the molecular result, rapidly growing tumors, persistent new pain, neurologic deficits, or vision changes require prompt clinical assessment.
- NF1 may be diagnosed clinically, molecularly, or through a combination of both under revised international criteria.
- A pathogenic NF1 variant supports an autosomal dominant condition with highly variable expression.
- Young children with only café-au-lait macules may have NF1, Legius syndrome, or another pigmentary condition.
- Comprehensive testing should address sequencing, splice variants, and deletions or duplications.
- A blood test can miss mosaic NF1 when the variant is present in only a small proportion of cells.
- A variant of uncertain significance should not be used alone for tumor surveillance decisions or predictive testing of relatives.
Table of Contents
- Why NF1 Genetic Testing Is Ordered
- Clinical Criteria and the Legius Syndrome Differential
- NF1 Laboratory Methods and Mosaic Testing
- How to Interpret NF1 Test Results
- Surveillance From Childhood Through Adulthood
- Plexiform Neurofibromas and Tumor Warning Signs
- Inheritance, Family Testing, and Reproductive Planning
- Questions to Ask After NF1 Testing
Why NF1 Genetic Testing Is Ordered
NF1 findings emerge over time. Café-au-lait macules often appear in infancy, skin-fold freckling in early childhood, and cutaneous neurofibromas more commonly around puberty or adulthood. A child may therefore have a genuine NF1-related variant years before enough age-dependent features are visible for a purely clinical diagnosis.
Genetic testing is particularly helpful when a young child has multiple café-au-lait macules, when the family history is absent or uncertain, when findings are limited to one body segment, or when the distinction from another syndrome changes surveillance. It may also clarify an atypical presentation involving an optic pathway glioma, plexiform neurofibroma, tibial bowing, sphenoid wing dysplasia, or a family pattern of NF1.
Testing can change care before symptoms develop
A confirmed diagnosis prompts age-specific eye examinations, blood-pressure monitoring, developmental and school assessment, skeletal review, and education about tumor warning signs. In an at-risk child, testing is not merely predictive of an adult-onset condition; it can guide care immediately.
Testing also allows relatives who did not inherit the family variant to avoid NF1-specific surveillance. That benefit depends on first identifying a clearly pathogenic variant in an affected family member.
Testing the affected person first
When a family contains several possibly affected people, the most informative starting point is usually the person with the clearest clinical diagnosis. If the laboratory finds a pathogenic NF1 variant, relatives can receive a focused familial variant test rather than an open-ended analysis.
A negative result in an unaffected relative is difficult to interpret when no familial variant has been established. It does not prove that the family’s condition is absent or that the original diagnosis was correct.
NF1 in tumor sequencing is a different question
NF1 is frequently altered only within tumor cells in many sporadic cancers. An NF1 variant found on a tumor profiling report does not automatically mean the person has constitutional neurofibromatosis type 1. Germline testing on blood, saliva, or another non-tumor sample is needed, together with clinical evaluation. Variant allele fraction and tumor purity can provide clues but are not definitive.
Clinical Criteria and the Legius Syndrome Differential
Revised international criteria recognize both established clinical features and molecular evidence. In a person without an affected parent, diagnosis generally requires at least two qualifying features. These include characteristic café-au-lait macules, axillary or inguinal freckling, neurofibromas or a plexiform neurofibroma, optic pathway glioma, characteristic ocular findings, distinctive bone lesions, or a heterozygous pathogenic NF1 variant identified in unaffected tissue. The exact combinations should be assessed by a clinician familiar with the criteria.
If a parent meets NF1 criteria, fewer additional findings may be needed in the child. Still, a family resemblance or one café-au-lait macule is not enough. Documenting lesion number, size, distribution, and age helps avoid both delayed diagnosis and overdiagnosis.
Café-au-lait macules are not specific to NF1
Multiple café-au-lait macules occur in NF1, but they can also be seen in Legius syndrome, constitutional pigment variation, constitutional mismatch repair deficiency, Noonan syndrome with multiple lentigines, McCune-Albright syndrome, and other conditions. The differential depends on the distribution, associated features, family history, and ancestry.
Legius syndrome is caused by pathogenic variants in SPRED1. It can produce café-au-lait macules, skin-fold freckling, macrocephaly, and learning or attention difficulties, but it does not carry the characteristic NF1 risk for neurofibromas, plexiform neurofibromas, optic pathway glioma, or malignant peripheral nerve sheath tumor. In a child whose only findings are pigmentary, testing both NF1 and SPRED1 can prevent years of uncertainty and inappropriate tumor counseling.
Features that strengthen an NF1 diagnosis
A plexiform neurofibroma is highly characteristic. Other supportive findings include Lisch nodules of the iris, choroidal abnormalities detected by near-infrared imaging, optic pathway glioma, anterolateral tibial bowing or pseudarthrosis, and sphenoid wing dysplasia. Cutaneous neurofibromas are usually benign and become more numerous with age.
Learning disability, attention-deficit/hyperactivity disorder, speech or motor delay, short stature, macrocephaly, scoliosis, headaches, and hypertension are important in care but are not individually specific enough to diagnose NF1.
Variable expression within one family
NF1 has very high penetrance, meaning most people with a germline pathogenic variant develop recognizable features over a lifetime. Expression is highly variable, however. A mildly affected parent can have a child with significant plexiform tumors, learning needs, or bone disease, and the reverse can occur. Most variants do not allow a precise severity forecast.
A few genotype–phenotype associations are recognized. Whole-gene deletions may be associated with a larger tumor burden and more severe manifestations; certain recurrent variants can be associated with pigmentary-only or other characteristic patterns. These correlations can inform counseling but do not replace individual surveillance.
NF1 Laboratory Methods and Mosaic Testing
NF1 is a large gene with many exons, numerous possible pathogenic variants, and a high rate of splice-altering changes. Testing strategy matters because a basic DNA panel may not detect every clinically important mechanism.
Sequencing with RNA analysis
DNA sequencing identifies nonsense, frameshift, missense, canonical splice-site, and small insertion or deletion variants. Because many NF1 variants disrupt splicing outside the most obvious splice positions, some laboratories analyze messenger RNA or complementary DNA from cultured cells. RNA analysis can reveal exon skipping or abnormal transcripts that DNA-only interpretation might miss.
The report should state whether RNA-based testing was performed, whether the assay can detect low-level mosaic variants, and which regions had insufficient coverage. A high-quality comprehensive assay has a higher detection rate than exome sequencing alone.
Deletion and duplication analysis
Exon-level deletions, duplications, and whole-gene deletions require copy-number analysis. Methods can include read-depth analysis, multiplex ligation-dependent probe amplification, chromosomal microarray, or other validated techniques. A whole-gene deletion may extend into neighboring genes and produce a recognizable microdeletion phenotype.
If sequencing is negative, it is important to confirm that deletion/duplication testing was actually completed rather than assumed. The laboratory may recommend chromosomal microarray when a large deletion is suspected.
Multigene panels
A pigmentary-disorder panel may include NF1 and SPRED1. A broader tumor-predisposition or RASopathy panel may be appropriate when developmental, cardiac, facial, blood, or cancer findings suggest another condition. Panels increase the chance of an answer but also create more variants of uncertain significance.
The largest panel is not automatically the best. Gene selection should match the phenotype and include only genes with established disease relationships and interpretable management implications.
Mosaic or segmental NF1
Mosaic NF1 occurs when the pathogenic variant arises after fertilization. Findings may be limited to one side, one limb, a band of skin, or a subset of tissues, although generalized mosaic disease can also occur. The variant level in blood may be low or undetectable.
When clinical suspicion is strong but blood testing is negative, testing affected tissue may be considered. For pigmentary lesions, specialized sampling of melanocytes may be more informative than a routine skin biopsy containing mixed cell types. For neurofibromas, demonstration of the constitutional “first hit” requires careful tumor analysis because tumors also acquire a second NF1 alteration.
Mosaicism changes reproductive counseling. A person with localized mosaic findings may have a lower than 50% transmission risk, but the exact risk depends on whether reproductive cells carry the variant and usually cannot be measured directly.
How to Interpret NF1 Test Results
A report should be interpreted in the context of clinical criteria, age, sample type, and assay sensitivity. The same word—positive or negative—can carry different implications in a child with six café-au-lait macules, an adult with classic NF1, and a tumor-only specimen.
Pathogenic or likely pathogenic result
A heterozygous pathogenic or likely pathogenic NF1 variant in blood or another unaffected tissue supports a constitutional diagnosis when the phenotype is compatible. Under revised criteria, molecular evidence can combine with one other qualifying feature to establish NF1 in many situations.
A positive result does not mean cancer is present. NF1 is a tumor-predisposition condition, not a diagnosis of malignancy. It also cannot predict the number of cutaneous neurofibromas, whether an optic pathway glioma will occur, or which child will need treatment for a plexiform neurofibroma.
The exact variant should be preserved in the family record. Relatives need the laboratory’s nucleotide and protein notation, not a description such as “the NF gene.”
Variant of uncertain significance
A variant of uncertain significance, or VUS, lacks enough evidence to be classified as disease-causing or benign. It should not establish NF1, trigger imaging of every organ, justify tumor surgery, or be used as a predictive test in healthy relatives.
A person with convincing clinical NF1 still receives appropriate care even if testing shows only a VUS. Conversely, an otherwise healthy person with a VUS should not be labeled with NF1. Family segregation, RNA analysis, phenotype matching, and later reclassification may resolve the finding.
Negative result
A negative comprehensive test reduces the likelihood of NF1 but does not exclude it. A clinically diagnosed person may have mosaicism, a deep intronic variant, a complex rearrangement, or a change not detectable by the assay. Care should follow the clinical diagnosis while additional testing is considered.
In a young child with pigmentary findings only, a negative NF1 test should prompt review of assay completeness and consideration of SPRED1 or another diagnosis. The result should not be treated as proof that future NF1 features cannot emerge unless the evaluation supports a different confirmed cause.
A negative targeted result for a known familial pathogenic variant is much more informative. The relative has not inherited that family variant and usually does not need NF1 surveillance because of it, unless separate clinical findings warrant evaluation.
Benign result or pseudogene artifact
Benign and likely benign variants do not cause NF1. Technical artifacts can occur because NF1 has homologous pseudogene sequences. Clinical laboratories use validated methods and confirmation to avoid reporting a pseudogene change as a patient variant. Consumer raw data or research calls should be confirmed before any medical decision.
Surveillance From Childhood Through Adulthood
NF1 surveillance is age-specific and primarily clinical. Routine screening tests should target complications that can be detected early and acted upon; indiscriminate repeated imaging can lead to sedation, radiation, incidental findings, and unnecessary procedures.
Childhood follow-up
Children generally need at least annual review by a clinician familiar with NF1. Visits assess skin and plexiform tumors, growth and head circumference, blood pressure, pubertal development, scoliosis and limb asymmetry, pain, neurologic symptoms, development, school progress, attention, and behavior.
Formal ophthalmologic examination is important in young children because optic pathway glioma risk is concentrated in early childhood and children may not report visual loss. Visual acuity, color vision, pupils, eye movements, and optic nerves are assessed at intervals guided by age and findings. Routine brain MRI is not universally recommended for an asymptomatic child with reliable normal eye examinations; imaging is used when examination is abnormal, unreliable, or symptoms arise.
Early developmental intervention, speech therapy, educational support, and ADHD treatment can have substantial benefit. A genetic diagnosis should lead to proactive school assessment rather than an assumption that every child will have intellectual disability.
Adult follow-up
Adults need ongoing review for neurofibromas, plexiform tumors, pain, neurologic change, blood pressure, vascular symptoms, bone health, and psychosocial burden. Hypertension may be essential, renal-artery related, or caused by pheochromocytoma or paraganglioma. Sudden or episodic headache, palpitations, sweating, or difficult-to-control blood pressure deserves targeted evaluation.
Women with NF1 have an increased risk of breast cancer at younger ages. Breast screening may begin earlier than population programs, with the exact use of mammography and MRI based on current national guidance, age, breast density, prior radiation, and specialist assessment.
Whole-body MRI can estimate internal tumor burden in selected settings, and some European guidance considers an assessment around transition to adulthood. It is not a substitute for symptom-directed evaluation or universally repeated at fixed intervals for every patient. Local expertise and guidelines should determine use.
Pregnancy and anesthesia
Pregnancy can be associated with growth or increased symptoms from neurofibromas, and hypertension requires close attention. Most pregnancies are successful, but obstetric, anesthesia, and NF1 teams may need to review spinal tumors, scoliosis, vascular disease, and blood pressure before delivery.
Before surgery, clinicians should know about airway tumors, spinal abnormalities, vascular disease, and pheochromocytoma risk when clinically suspected. Routine procedures should not be denied solely because of NF1, but planning may need modification.
Plexiform Neurofibromas and Tumor Warning Signs
Plexiform neurofibromas grow along nerve branches and may be superficial or internal. Some are visible in childhood; others are found only by imaging. They can cause disfigurement, pain, weakness, airway or organ compression, and functional impairment.
When a change needs urgent assessment
Most neurofibromas are benign. Features concerning for malignant peripheral nerve sheath tumor or an atypical precursor include:
- new persistent or nighttime pain, especially pain that differs from the person’s usual pattern;
- rapid or sustained growth of a known mass;
- a change from soft to firm or hard texture;
- new weakness, numbness, loss of function, or bowel or bladder symptoms;
- unexplained weight loss or decline in general health.
These findings do not prove cancer, but they warrant prompt review at an NF1 or sarcoma center. Evaluation may use regional MRI, metabolic imaging, image-guided biopsy, and multidisciplinary review. Random biopsy of a large heterogeneous plexiform tumor can miss the most concerning area, so imaging-guided planning matters.
Treatment decisions
Observation is appropriate for many stable, asymptomatic tumors. Surgery is considered when a tumor can be removed with acceptable risk and is causing symptoms, disfigurement, progressive dysfunction, or concern for malignancy. Complete excision may be difficult because plexiform tumors intertwine with nerves and vessels.
MEK-inhibitor therapy may be considered for selected people with symptomatic, inoperable plexiform neurofibromas according to age, jurisdiction, current approvals, and specialist judgment. Treatment requires monitoring for cardiac, eye, skin, gastrointestinal, and laboratory adverse effects. A pathogenic NF1 result alone is not an indication for medication.
Other tumors
NF1 increases risk for optic pathway and other gliomas, pheochromocytoma, gastrointestinal stromal tumors, juvenile myelomonocytic leukemia in young children, and certain breast cancers, among others. Surveillance is not identical for every tumor. The preferred strategy is age-appropriate clinical review and rapid investigation of specific symptoms rather than frequent scans of all organs without indication.
Inheritance, Family Testing, and Reproductive Planning
NF1 is inherited in an autosomal dominant pattern. Each child of a person with a germline pathogenic NF1 variant has a 50% chance of inheriting it. The probability is the same for all sexes and resets with each pregnancy.
About half of affected people have a variant that arose newly in them. Even when neither parent has constitutional NF1, the affected person can transmit the variant to children. Parental examination and targeted testing help determine whether the result is inherited, de novo, or mosaic.
Testing relatives
First-degree relatives with possible findings should receive clinical examination and, when the familial variant is known, targeted testing. A relative who tests positive needs age-appropriate surveillance even if currently mild. A true-negative relative does not pass that family variant to children.
This follows standard autosomal dominant inheritance, but severity cannot be predicted from the parent’s appearance. Prenatal counseling should explicitly address variable expression.
Reproductive options
A known familial pathogenic variant can be tested through chorionic villus sampling or amniocentesis. In vitro fertilization with PGT-M can identify embryos that did not inherit the family variant before transfer. Neither approach can predict whether an affected child would have mild pigmentary findings or serious tumors and complications.
Other options include donor gametes, adoption, or natural conception without fetal testing. Decisions are personal and should be supported with balanced information about variability, available surveillance, treatment advances, pregnancy considerations, and the family’s values.
Mosaic reproductive risk
A person with mosaic NF1 may have less than a 50% chance of transmission, but the risk can range from very low to substantial depending on the proportion of reproductive cells carrying the variant. Blood variant fraction does not accurately measure egg or sperm involvement. If a mosaic variant is transmitted, the child may have the variant in all cells and could be more broadly affected than the parent.
Questions to Ask After NF1 Testing
Useful questions include:
- Do I or my child meet revised clinical NF1 criteria now?
- Was testing performed on blood, saliva, tumor, or affected tissue?
- Did the assay include NF1 sequencing, RNA or splice analysis, and deletion/duplication testing?
- Could low-level mosaicism explain a negative blood result or segmental findings?
- Should SPRED1 or another pigmentary or RASopathy gene be tested?
- Is the reported variant pathogenic, likely pathogenic, uncertain, or benign, and what evidence supports that classification?
- Does this variant have a recognized genotype–phenotype association, and how limited is that prediction?
- What eye, blood-pressure, developmental, skeletal, skin, and neurologic surveillance is due at this age?
- Which symptoms from a plexiform neurofibroma require urgent imaging?
- Is whole-body MRI appropriate, and what decision would it change?
- What breast screening is recommended under current local guidance?
- Which relatives should have targeted testing and clinical examination?
- How does mosaicism affect the chance of passing NF1 to a child?
- What prenatal or PGT-M options are available for the exact familial variant?
The most useful NF1 test interpretation separates diagnosis from prognosis. It confirms whether a constitutional disease-causing variant is present, explains the assay’s ability to detect mosaic and splice variants, and turns the result into an age-specific surveillance plan without implying that every possible complication will occur.
References
- Friedman JM. Neurofibromatosis 1. GeneReviews®, updated 2025. Expert clinical review.
- Legius E, et al. Revised Diagnostic Criteria for Neurofibromatosis Type 1 and Legius Syndrome: An International Consensus Recommendation. Genetics in Medicine, 2021. International consensus.
- Carton C, et al. ERN GENTURIS Tumour Surveillance Guidelines for Individuals With Neurofibromatosis Type 1. eClinicalMedicine, 2023. Clinical guideline.
- Perrino MR, et al. Update on Pediatric Cancer Surveillance Recommendations for Patients With Neurofibromatosis Type 1 and Other RASopathies. Clinical Cancer Research, 2024. Consensus surveillance update.
- Kerashvili N, Gutmann DH. The Management of Neurofibromatosis Type 1 in Children and Adolescents. Expert Review of Neurotherapeutics, 2024. Clinical review.
- Zheng Y, et al. Long-Read Sequencing for Comprehensive NF1 Gene Analysis. Human Molecular Genetics, 2025. Diagnostic methods study.
Disclaimer
This article is for general education and does not replace individualized care from genetics, neurology, oncology, ophthalmology, or an NF specialty clinic. Rapid tumor growth, new persistent pain, weakness, vision change, severe headache, or other acute neurologic symptoms require prompt medical assessment. Surveillance and imaging should follow the person’s age, manifestations, exact result, and current specialist guidelines.
